Abstract 261: Applying Clinical Trial Data to Real-World: Apixaban, Dabigatran, and Rivaroxaban [Session Title: Poster Session II]

CONCLUSIONS: If relative risk reductions from randomized clinical trials persist in the real-world, apixaban would result in the greatest clinical benefit versus warfarin of all NOACs in terms of stroke and major bleeding excluding intracranial hemorrhage events avoided.

Source: Circulation: Cardiovascular Quality and Outcomes - June 2, 2014 Category: Cardiology Authors: Amin, A., Stokes, M., Wu, N., Gatt, E., Makenbaeva, D., Wiederkehr, D., Lawrence, J. H. Tags: Session Title: Poster Session II Source Type: research